OX2R-004 (KGDRYGVAYEHGGAQPFK) is an 18-residue peptide designed as a selective agonist of human Orexin Receptor 2 (OX2R). The orexin system is implicated in ADHD pathophysiology — drug-naive children with ADHD show decreased orexin-A/B levels — yet no orexin-based therapy is approved for this indication, and all clinical-stage OX2R agonists are small molecules targeting narcolepsy (TAK-861, ORX750, BP1.15205). OX2R-004 represents a novel peptide modality for this space.
PeptAI
Research Lead
Therapeutic Relevance
Plausible orexin-ADHD link but G6 Fail, G4/G5 pending, and no experimental validation undermine…
Therapeutic Optionality
OX2R mechanism could extend to narcolepsy and sleep disorders, but OX1R cross-reactivity limits…
Intellectual Property
Novel peptide modality in a field of small-molecule agonists; no prior art for peptide OX2R…